Merck Sharp + Dohme Corp.

William J Smith

Michael Albert Winters

Chitrananda Abeygunawardana

Luwy Kavuka Musey

Patrick McHugh

Julie Marie Skinner

Jian He

Yadong Adam Cui

Michael J Kosinski

John E MacNair

Cecilia Giovarelli

John M Williams

Joseph G Joyce

Emily Wen

Denise K Nawrocki

Sheng-Ching Wang

Hari Pujar

Thomas Svab

Catherine Lancaster

The present invention provides pneumococcal conjugate vaccine formulations comprising surfactant systems incorporating polysorbate 20 or a combination of a poloxamer and a polyol.

Pneumococcal conjugate vaccine formulations

The invention is related to multivalent immunogenic compositions comprising more than onepolysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from anserotype conjugated to a carrier protein, wherein the serotypes ofare as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection againstinfection and diseases caused by. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

Compositions comprisingpolysaccharide-protein conjugates and methods of use thereof

The invention is related to multivalent immunogenic compositions comprising more than onepolysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from anserotype conjugated to a carrier protein, wherein the serotypes ofare as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection againstinfection and diseases caused by. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which polysaccharides obtained from bacterial capsules are conjugated to diphtheria toxin fragment B (DTFB) or a variant thereof. The immunogenic compositions may be multivalent pneumococcal polysaccharide conjugate compositions in which polysaccharides from one or moreserotypes are conjugated to diphtheria toxin fragment B (DTFB) and, optionally, additional polysaccharides from one or more differentserotypes are conjugated to one or more other carrier proteins.

Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier

The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides frombacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.

Enhancing immunogenicity ofpolysaccharide-protein conjugates

Growing community of inventors

Harleysville, PA, United States of America

William J Smith